Switching from originator rituximab (Rituxan, Genentech) to rituximab-abbs (Truxima, Teva) can save an institution up to $13,000 annually per patient while maintaining efficacy and safety, according to two studies presented at the 2021 virtual annual meeting of the American Society of Clinical Oncology (ASCO).
“The findings provide important real-world evidence and should help physicians build confidence in the clinical equivalence of biosimilar rituximab,” said Sandra